Jazz Pharmaceuticals submits FDA application for leukaemia treatment
European Pharmaceutical Review | April 07, 2017
Jazz Pharmaceuticals completed a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of Vyxeos (cytarabine and daunorubicin) liposome for injection.